This trial is evaluating whether Transitional-state food therapeutic nutrition supplement will improve 5 primary outcomes and 8 secondary outcomes in patients with Dementia. Measurement will happen over the course of Prior to enrollment (to determine eligibility at baseline, prior to study onset; week 0).
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. Transitional-state Food Therapeutic Nutrition Supplement is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Signs of dementia do not always equate to symptoms. Individuals with symptoms of dementia often have no cognitive impairment. Dementia is defined by the loss of functioning capability. Individuals with dementia are usually bed-ridden or in a caregiving role." - Anonymous Online Contributor
"Cognitive behavioral therapy may help to improve cognition in dementia. Exercise and activity, in the form of an exercise program, improves physical function in those with vascular dementia.\n" - Anonymous Online Contributor
"In the United States, approximately 8,000 people get DLB each year and about 8,400 people get AD. In 2014, about 5,800 people got DLB and 5,500 got AD in the United States. The annual number of people who get DLB is around three to five times more than the number of people who get AD\n" - Anonymous Online Contributor
"The most important treatments of dementia, including Alzheimer's disease, have proved to be ineffective. For this reason, there is no convincing evidence that any specific treatment exists that would result in an improvement in the natural history of dementia." - Anonymous Online Contributor
"Dementia is a disorder of cognitive functioning that manifests as cognitive deficits in several areas of functioning that are clinically significant. It has a major negative impact on the ability to function at work, carry out daily routines or express identity.\n" - Anonymous Online Contributor
"The exact cause is unknown, though genetics, diabetes, brain lesions, immune disorders and infection can all affect cognition. As for other illnesses, the brain's ability to handle stress is usually affected first. When that is not sufficient, the body's natural defences will try to fight off the infection. When the disease has become too overwhelming, a number of symptoms can develop, most notably confusion, memory loss, dementia and psychosis.\n" - Anonymous Online Contributor
"The most significant therapeutic research has not included studies for treating dementia, but rather studies to delay or prevent loss of ability to perform basic functions of daily living (ADLs). As our focus on cognition and neural plasticity grow, we realize we need treatments to help dementia patients maintain their ability to integrate themselves into society. More research is needed to slow or prevent cognitive loss and to preserve or enhance ability to perform ADLs." - Anonymous Online Contributor
"The common side effects of food therapeutic nutrition supplements were nausea, dizziness and vomiting. Some people have the condition of drug-induced vomiting and nausea and the gastrointestinal effect of food therapeutic nutrition supplements. Allergic reactions were rare and were almost always associated with food therapeutic nutrition supplements." - Anonymous Online Contributor
"The majority of patients admitted to the rehabilitation unit received TFNS.TFNS was given daily to most patients, and was well tolerated. This is a safe adjunct therapy that can promote adherence to the treatment strategy and facilitate the gradual transition to the dietary home and long-term outcomes. TFNS may also be used as a tool in adherence evaluations and research studies." - Anonymous Online Contributor
"Researching for the National Institute of Aging shows that research is crucial for the development of therapeutic options for dementia patients. One of the most important questions for all clinical researchers working on Alzheimer's disease and other age-related dementias is, 'who should be included.' Although the current population is incredibly diverse with respect to age, ethnicity, sex, comorbidities, and dementia severity, there is a large body of research which has shown improvements in functional outcomes of Alzheimer's patients who received treatments that included clinical trials. Even though Alzheimer's disease constitutes only a small percentage of the U.S. population, studies have established that clinical trials could lead to positive and effective effects if they include a sufficient number of individuals." - Anonymous Online Contributor
"A large proportion of dementia cases are idiopathic, i.e. they cannot be explained by any single known risk factor. The other factors which increase the risk of Alzheimer's disease are related to the timing of diagnosis. In addition, the occurrence of stroke is frequently preceded by transient ischemic attack, which can also lead to dementia. In all these cases, age and genetic factors appear to be implicated." - Anonymous Online Contributor
"There is a need for the development and/or deployment of reliable and efficient clinical trials, aimed to validate and substantiate the feasibility of food supplements for improving nutritional status and function of people with severe disability associated with nutritional imbalances." - Anonymous Online Contributor